{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:47:26Z","timestamp":1791002846488,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T00:00:00Z","timestamp":1497398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal impairment is a common complication of multiple myeloma and deterioration in renal function or renal failure may complicate clinical management. This retrospective study in patients with multiple myeloma using an electronic medical records database was designed to estimate the prevalence of renal impairment (single occurrence of estimated glomerular filtration rate [<jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>] &lt;60<jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\/min per 1.73\u00a0m<jats:sup>2<\/jats:sup>on or after multiple myeloma diagnosis) and chronic kidney disease (at least two<jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>values &lt;60<jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content>\/min per 1.73\u00a0m<jats:sup>2<\/jats:sup>after multiple myeloma diagnosis that had been measured at least 90\u00a0days apart), and to describe the use of nephrotoxic agents. Eligible patients had a first diagnosis of multiple myeloma (<jats:styled-content style=\"fixed-case\">ICD<\/jats:styled-content>\u20109<jats:styled-content style=\"fixed-case\">CM<\/jats:styled-content>: 203.0x) between January 1, 2012 and March 31, 2015 with no prior diagnoses in the previous 6\u00a0months. Of 12,370 eligible patients, the prevalence of both renal impairment and chronic kidney disease during the follow\u2010up period was high (61% and 50%, respectively), and developed rapidly following the diagnosis of multiple myeloma (6\u2010month prevalence of 47% and 27%, respectively). Eighty percent of patients with renal impairment developed chronic kidney disease over the follow\u2010up period, demonstrating a continuing course of declining kidney function after multiple myeloma diagnosis. Approximately 40% of patients with renal impairment or chronic kidney disease received nephrotoxic agents, the majority of which were bisphosphonates. As renal dysfunction may impact the clinical management of multiple myeloma and is associated with poor prognosis, the preservation of renal function is critical, warranting non\u2010nephrotoxic alternatives where possible in managing this population.<\/jats:p>","DOI":"10.1002\/cam4.1075","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T06:06:42Z","timestamp":1497420402000},"page":"1523-1530","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5570-7693","authenticated-orcid":false,"given":"Yi","family":"Qian","sequence":"first","affiliation":[{"name":"Global Health Economics Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debajyoti","family":"Bhowmik","sequence":"additional","affiliation":[{"name":"Global Health Economics Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bond","sequence":"additional","affiliation":[{"name":"Covance Gaithersburg Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Wang","sequence":"additional","affiliation":[{"name":"Covance Gaithersburg Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Colman","sequence":"additional","affiliation":[{"name":"Covance Gaithersburg Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini K.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Center for Observational Research Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cheng","sequence":"additional","affiliation":[{"name":"Global Development Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Intorcia","sequence":"additional","affiliation":[{"name":"Global Health Economics Amgen Inc. Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117176"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.131"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01318.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.07.010"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62051-X"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06698.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.17.1889"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb00190.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(25)00115-6","article-title":"Multiple myeloma: review of 869 cases","volume":"50","author":"Kyle R. A.","year":"1975","journal-title":"Mayo Clin. Proc."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90221.x"},{"key":"e_1_2_8_12_1","unstructured":"Quach D. A.Liede S.Byekwaso D.Eremina B.Kossar L.Zhou et\u00a0al.2013.Projection Methods Using Oncology Electronic Health Records to Produce Nationally Representative Estimates. obroncologycom\/imshealth\/content\/ISPE%202013_Quach%20poster_13Aug2013pdf. 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (Montreal Canada):August 25\u20108."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.403"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.0044"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.20"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.1075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.1075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T15:27:26Z","timestamp":1750346846000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.1075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,14]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/cam4.1075"],"URL":"https:\/\/doi.org\/10.1002\/cam4.1075","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,14]]},"assertion":[{"value":"2016-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}